GlassScriptPhysician profile
Christine Dillingham
NPI 1992190870
$2,809.66
in general payments reported to CMS, 2019-2025
19 companies · $607 in 2025
The $607 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $11.22 · 2021: $337 · 2022: $21.44 · 2023: $57.10 · 2024: $1,776 · 2025: $607.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,299 · Food and Beverage: $1,100 · Consulting Fee: $21.39 · Education: $19.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,298.99 |
| Food and Beverage | $1,099.60 |
| Consulting Fee | $21.39 |
| Education | $19.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $1,751.25 | 2024-2025 | Tarpeyo |
| Amgen INC. | $161.08 | 2021-2025 | Krystexxa, Tavneos |
| Bayer Healthcare Pharmaceuticals INC. | $140.88 | 2025 | |
| Opko Pharmaceuticals, LLC | $115.88 | 2021-2023 | Rayaldee |
| Otsuka America Pharmaceutical, INC. | $102.96 | 2020-2025 | Jynarque, Rexulti |
| Mallinckrodt Hospital Products INC. | $85.77 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.70 | 2025 | Jardiance |
| Boston Scientific Corporation | $73.31 | 2022-2025 | Wavewriter Alpha Prime 16, Intracept |
| Conmed Corporation | $60.29 | 2024 | Airseal |
| Ani Pharmaceuticals, INC. | $49.02 | 2025 | Purified Cortrophin Gel |
| Daiichi Sankyo INC. | $34.61 | 2021-2025 | Injectafer |
| Alexion Pharmaceuticals, INC. | $26.60 | 2021 | |
| Exact Sciences Corporation | $26.17 | 2025 | Cologuard Collection Kit |
| Vifor Pharma, INC. | $23.93 | 2025 | Veltassa |
| Novo Nordisk INC | $21.72 | 2025 | Ozempic |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $18.69 | 2025 | |
| Shield Therapeutics INC | $16.78 | 2023 | Accrufer |
| Takeda Pharmaceuticals U.S.A., INC. | $16.45 | 2025 | Trintellix |
| Phathom Pharmaceuticals, INC. | $10.57 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christine Dillingham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.